Emerging Evidence on GLP-1 Therapies and Atrial Fibrillation Risk Recent studies exploring the link between GLP-1 therapies and atrial fibrillation present mixed findings
Available from: 15
Mir Ali, MD, board certified general surgeon, bariatric surgeon and medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA, not involved in this research, said that this study was helpful to show that some muscle can occur with significant weight loss. We see this in our surgical weight loss patients as well, and try to emphasize methods to minimize muscle loss, he told MNT
The other part is choosing between semaglutide and tirzepatide
Over the course of several weeks or months, you may experience a noticeable reduction in appetite and cravings
[1] [3] Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist with similar clinical effects